Merck, Daiichi Sankyo withdraw ifinatamab deruxtecan U.S. BLA in small cell lung cancer

The companies said the U.S. biologics license application for ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer was voluntarily withdrawn after discussions with the FDA. Enrollment continues in a Phase 3 trial of the drug in relapsed ES-SCLC.